Matwings Unveils Advanced Protein Engineering with AI-Driven Approach in New Therapeutic Program#China#Shanghai#Protein_Engineering#Matwings#GenSci148
Matwings Unveils Advanced Protein Engineering with AI-Driven Approach in New Therapeutic Program
Matwings Technology showcases its innovative AI-guided protein engineering techniques through the GenSci148 program, which aims to revolutionize therapeutic development.
third-news.com
August 20, 2026 at 11:16 AM
Matwings Unveils Advanced Protein Engineering with AI-Driven Approach in New Therapeutic Program#China#Shanghai#Protein_Engineering#Matwings#GenSci148
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
July 8, 2026 at 9:39 AM
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
July 8, 2026 at 9:39 AM
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
July 8, 2026 at 9:50 AM
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
July 8, 2026 at 9:45 AM
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
July 8, 2026 at 9:39 AM
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
July 8, 2026 at 9:33 AM
[2/3] Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci148 injection was accepted. GenSci148 injection is a VEGF multiple blocker independently developed by Kinsey Pharmaceuticals. It is intended to be used to treat
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
July 8, 2026 at 9:45 AM
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
July 8, 2026 at 9:39 AM
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
July 8, 2026 at 9:50 AM
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
July 8, 2026 at 9:33 AM
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
July 8, 2026 at 9:39 AM
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State
July 8, 2026 at 9:39 AM
[1/3] 2026-07-08 16:55:55 - [Changchun High-tech: The subsidiary GenSci148 injection clinical trial application was accepted] Changchun High-tech announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the "Acceptance Notice" approved and issued by the State